RGNX - Regenxbio

-

$undefined

N/A

(N/A)

Regenxbio NasdaqGS:RGNX REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Location: 9804 Medical Center Drive, Rockville, MD, 20850, United States | Website: https://www.regenxbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

315.6M

Cash

267.9M

Avg Qtr Burn

-21.01M

Short % of Float

15.33%

Insider Ownership

7.59%

Institutional Own.

88.18%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Clemidsogene lanparvovec (RGX-121) Details
Mucopolysaccharidosis II (MPS II), aka Hunter syndrome

PDUFA

Approval decision

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Diabetes, Eye disease , Diabetic retinopathy

Phase 3

Initiation

RGX-202 Details
Rare diseases, Genetic disorder, Rare genetic disease, Duchenne muscular dystrophy

Phase 2/3

Update

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Eye disease , Age-related macular degeneration, Wet age-related macular degeneration

Phase 2

Data readout

ABBV-RGX-314 (Subretinal Delivery) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Data readout

RGX-381 Details
Central nervous system illness

Phase 1/2

Data readout

RGX-111 Details
Mucopolysaccharidoses, Rare genetic disease, Genetic disorder, Rare diseases, Mucopolysaccharidosis Type 1

Phase 1/2

Update

RGX-181 Details
Central nervous system illness, Batten Disease

Phase 1

Data readout